Literature DB >> 23669798

Assessing process of care in rheumatoid arthritis at McGill University hospitals.

Lisa Marina Li1, Basile Tessier-Cloutier, Yafei Wang, Sasha Bernatsky, Evelyne Vinet, Henri André Ménard, Pantelis Panopalis, Elizabeth Hazel, Michael Stein, Martin Cohen, Michael Starr, Christian Pineau, Marie-Ève Veilleux, Inés Colmegna.   

Abstract

OBJECTIVE: In rheumatoid arthritis (RA), quality indicators (QIs) are tools used to measure process of care. This study aimed to assess performance of selected QIs from the 2004 Arthritis Foundation's QI Set at 2 major sites of a university network of teaching hospitals.
METHODS: The charts and electronic hospital records of 76 RA patients were audited to determine adherence to QIs. Logistic multivariate regression analyses were performed to investigate potential determinants of nonadherence and propose measures to facilitate better QI compliance, as a potential strategy towards RA care improvement.
RESULTS: We identified consistent observance of QIs mandating prescription of disease-modifying antirheumatic drug therapy for all patients, drug adjustment with disease activity, prednisone tapering, and bisphosphonate therapy if indicated for patients on glucocorticoids. However, there was either lack of documentation or true inconsistent adherence to QIs dealing with radiograph performance, functional capacity assessment, and screening for hepatitis and tuberculosis before commencement of methotrexate and biologic agents, respectively. For the specific QIs analyzed, we did not find any definite independent associations with the studied variables.
CONCLUSIONS: Our findings indicate that while there is frequent evidence for adherence to certain RA quality care standards at our centers, there is less compliance to others. Strategies to optimize the performance or documentation of those found most lacking, namely, functional capacity and screening for specific drug contraindications, could improve patient care. Radiographic disease monitoring, while lacking, may represent a move toward other more sensitive methods of RA progression detection, such as joint ultrasound. The inclusion of patient- and physician-derived information could help elucidate the reasons underlying nonadherence.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23669798     DOI: 10.1097/RHU.0b013e3182937094

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  4 in total

1.  Timing and Impact of Decisions to Adjust Disease-Modifying Antirheumatic Drug Therapy for Rheumatoid Arthritis Patients With Active Disease.

Authors:  Yomei Shaw; Chung-Chou H Chang; Marc C Levesque; Julie M Donohue; Kaleb Michaud; Mark S Roberts
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-04-16       Impact factor: 4.794

Review 2.  A systematic review of the barriers affecting medication adherence in patients with rheumatic diseases.

Authors:  Hendra Goh; Yu Heng Kwan; Yi Seah; Lian Leng Low; Warren Fong; Julian Thumboo
Journal:  Rheumatol Int       Date:  2017-07-05       Impact factor: 2.631

3.  Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications.

Authors:  Sarah Patterson; Gabriela Schmajuk; Michael Evans; Ishita Aggarwal; Zara Izadi; Milena Gianfrancesco; Jinoos Yazdany
Journal:  Jt Comm J Qual Patient Saf       Date:  2019-01-25

4.  RISE registry reveals potential gaps in medication safety for new users of biologics and targeted synthetic DMARDs.

Authors:  Gabriela Schmajuk; Jing Li; Michael Evans; Christine Anastasiou; Zara Izadi; Julia L Kay; Nevin Hammam; Jinoos Yazdany
Journal:  Semin Arthritis Rheum       Date:  2020-03-19       Impact factor: 5.532

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.